Aldeyra shares soar on pos­i­tive PhII dry eye da­ta — but lose some steam on sec­ond look

Shares of Aldeyra Ther­a­peu­tics $ALDX soared in pre-mar­ket trad­ing Wednes­day as the biotech tout­ed pos­i­tive da­ta for its lead drug in treat­ing dry eye dis­ease. But the fren­zy al­so start­ed to wane rather ear­ly as the da­ta got a sec­ond look from skep­tics.

Their drug is re­prox­alap, and their state­ment ze­roed in on the sta­tis­ti­cal­ly sig­nif­i­cant scores re­searchers record­ed in a Phase IIb tri­al, com­ing in some­where un­der the wire at a p val­ue of <0.05 for two dos­es rat­ed on the Four-Symp­tom Oc­u­lar Dry­ness Score and the Over­all Oc­u­lar Dis­com­fort Symp­tom Score.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER